Trial ID or NCT#
This phase II trial studies how well pembrolizumab works in treating patients with Merkel cell cancer that cannot be removed by surgery or controlled with treatment, or has spread to other parts of the body. Pembrolizumab may stimulate the immune system to identify and destroy cancer cells.
A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
Contact us to find out if this trial is right for you.